

5. (Amended) The antibody according to claim 1 [any of the preceding claims], which is linked to a marker.

6. (Amended) The antibody according to claim 1 [any of the claims 1 or 2], which is derived from the hybridoma cell line CNCM I-2476.

7. (Amended) ~~The use~~ [Use] of an antibody according to claim 1 any of the claims 1 to 6 or a functional part thereof for the diagnosis and/or treatment of Bovine Spongiform Encephalopathy or Creutzfeld-Jacobs-Disease or a variant form of Creutzfeld-Jacobs-Disease or TSE related diseases.

8. (Amended) The use of an antibody according to claim 1 [any of the claims 1 to 6] for the production of a drug against BSE and/or CJD and/or vCJD or TSE related diseases.

9. (Amended) The use of an antibody according to claim 1 [any of the claims 1 to 6] for the production of an active and/or passive vaccine against BSE, CJD, vCJD or TSE related diseases.

10. (Amended) A method of producing an antibody according to claim 1 [any of the claims 1 to 6] comprising the step of immunizing an animal with an amount of a peptide having the amino acid sequence

-Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

or

-Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

or a variant thereof, obtained by substituting, deleting or adding one or more amino acids with the proviso that the three dimensional conformation is essentially retained, sufficient to elicit an immune response.

11. (Amended) ~~A kit~~ [Kit] for the diagnosis and/or the treatment of BSE and/or CJD and/or vCJD or TSE related diseases, containing an antibody according to claim 1 [any of the claims 1 to 6].

~~5/20/00~~ 12. (Amended) ~~A pharmaceutical~~ [Pharmaceutical] composition, comprising an antibody according to claim 1 [any of the claims 1 to 6].

13. (Amended) ~~A hybridoma~~ [Hybridoma] cell line capable of producing [to produce] an antibody according to claim 1 [any of the claims 1 to 6].

15. (Amended) ~~An antibody~~ [Antibody] directed to the idiotype of an antibody according to claim 1 [any of the claims 1 to 6].

Respectfully submitted,



Michael L. Goldman
Registration No. 30,727

Date: May 23, 2000

NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603
Telephone: (716) 263-1304
Facsimile: (716) 263-1600